Comparison of neoadjuvant nab-paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma.

Yafan Yang,Haomiao Li,Xiankai Chen,Jianjun Qin,Yong Li,Yaxing Shen,Ruixiang Zhang,Xiaozheng Kang,Zhen Wang,Qingfeng Zheng,Peng Luo,Yin Li,Jie He

Thoracic cancer（2023）

引用 4|浏览29

暂无评分

摘要

It appears to be feasible to add immunotherapy to nabTP regimen for locally advanced ESCC. Compared with TP, nabTP plus ICIs can achieve a better pCR rate in ESCC.

查看译文

关键词

Paclitaxel esophageal squamous cell carcinoma,immunotherapy,nab-,paclitaxel

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要